Literature DB >> 11075088

Portal vein thrombosis and liver disease.

P A Radovich1.   

Abstract

Portal vein thrombosis can occur secondary to infection, surgical intervention, or as a result of liver dysfunction. Its development can precipitate the need for emergency interventions including endoscopy, transjugular intrahepatic portosystemic stents (TIPS), portacaval shunts, or even liver transplantation. Portal vein thrombosis occurs slowly and silently. Portal vein thrombosis is not discovered until gastrointestinal hemorrhage develops in the patient unless the thrombosis is diagnosed on routine surveillance diagnostic testing. Portal vein thrombosis can be diagnosed by Doppler ultrasonography, computed tomography scan, or magnetic resonance imaging. Late identification of portal vein thrombosis can lead to increased morbidity and mortality of the patient population. Patients with portal vein thrombosis can be successfully managed with early identification and collaboration between the patient and the health care team for ongoing monitoring and treatment. Patient education involves assisting the patient in the understanding of esophageal varices, the various treatment modalities, their physical limitations, and the need for monitoring and management of the portal hypertension.

Entities:  

Mesh:

Year:  2000        PMID: 11075088     DOI: 10.1016/s1062-0303(00)90052-9

Source DB:  PubMed          Journal:  J Vasc Nurs        ISSN: 1062-0303


  3 in total

1.  The difficult transjugular intrahepatic portosystemic shunt: alternative techniques and "tips" to successful shunt creation.

Authors:  Hector Ferral; Jose Ignacio Bilbao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

2.  Portal vein thrombosis and pancreatic failure.

Authors:  N A Afzal; M J Brueton; J M Fell; A Baker
Journal:  Int J Pancreatol       Date:  2001

3.  Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma.

Authors:  Long Sun; Yong-Song Guan; Wei-Ming Pan; Gui-Bing Chen; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.